I think that the Australian share market is home to a great number of small cap shares with enormous growth potential.
Five up and coming shares that I think investors should be keeping a close eye on in April are listed below. Here's why:
Bubs Australia Ltd (ASX: BUB)
This fledgling goat's milk infant formula company is aiming to win a share of the massive Chinese market and has been making great strides towards achieving this goal. The company has signed several distribution agreements with mother and baby stores and e-commerce platforms in the country. This has not yet translated into sales, however, so I think investors should wait to see if its product is a hit with consumers before investing.
Money3 Corporation Limited (ASX: MNY)
I have been very impressed at the performance of this financial services company's secured auto loans business. For the first-half of FY 2018 Money3 reported a 12.3% increase in net profit after tax to $15.5 million thanks to an 18% increase in its gross loan book. Considering the company still only has a 2% share of the second-hand automotive finance market, I think Money3 still has a long runway for growth ahead of it.
National Veterinary Care Ltd (ASX: NVL)
In the first-half of FY 2018 this growing veterinary company posted a 27.6% increase in revenue to $41.6 million and a 27.7% lift in net profit after tax to $3.3 million. I expect more of the same in the second-half and beyond thanks to the solid organic growth it is generating and the growth through acquisition opportunities it has in a highly fragmented industry.
Redbubble Ltd (ASX: RBL)
I've been very impressed at the growth of this e-commerce platform provider. For the first-half of FY 2018 Redbubble reported revenue of $102.3 million, up an impressive 30% on the prior corresponding period. With management confident that there's more of the same ahead in the second-half, investors might want to take a closer look at Redbubble.
Volpara Health Technologies Ltd (ASX: VHT)
This digital health company's technology enables personalised, high quality breast cancer screening based on automated, objective measurements of breast density, compression and radiation dose. Annual recurring revenues are expected to exceed its full-year 200% growth target this year. I think this level of growth makes Volpara one to watch.
